Long-Term Effects of Nilvadipine against Progression of the Central Visual Field Defect in Retinitis Pigmentosa: An Extended Study

Table 1

Background clinical data for patients in the treated and control groups.

	Treated group	Control group	Statistical significance
Number of patients	19	22
Gender (M/F)	9/10	10/12
Age, years at enrollment	51.84±10.94	48.41±16.03	0.583
Median (range), years	52 (28–72)	49 (22–73)	0.168
Age, years at initial symptom or diagnosis	41.11±1450	31.91±19.47	0.105
Median (range), years	45 (10–66)	26 (6–72)	0.019*
Observation period, months	72.32±24.29	65.73±22.26	0.324
Median (range), months	78 (30–120)	78 (36–120)	0.087
Initial MD value, R, dB	−17.50±10.82	−18.03±6.21	0.896
Median (range), dB	−16.81 (−32.22~+0.69)	−17.88 (−29.92~−7.83)	0.647
Initial MD value, L, dB	−18.12±11.34	−17.63±6.70	0.834
Median (range), dB	−15.90 (−33.44~+0.24)	−16.57 (−27.72~−4.50)	0.647
Correlation between R and L	0.96	0.82	<0.001 (T, C)**
Initial sensitivity in CENT4, R, dB	24.67±7.89	24.57 ± 6.02	0.935
Median (range), dB	24.75 (11.75–36.75)	23.75 (13.00–34.75)	0.342
Initial sensitivity in CENT4, L, dB	24.44±7.54	23.40 ± 7.65	0.616
Median (range), dB	24.25 (14.25–36.75)	21.50 (12.00–34.75)	0.342
Correlation between R and L	0.80	0.63	<0.001 (T)**; 0.002 (C)**

Data are expressed as means ± standard deviation.
M: male; F: female; R: right eye; L: left eye; T: treated group; C: control group.
Significance: ^∗𝑃≦0.05; ^∗∗𝑃<0.01.